{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T22:49:32Z","timestamp":1767134972912,"version":"build-2238731810"},"update-to":[{"DOI":"10.1002\/14651858.cd008270","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2013,6,5]],"date-time":"2013-06-05T00:00:00Z","timestamp":1370390400000}}],"reference-count":68,"publisher":"Wiley","issue":"6","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd008270.pub2","type":"journal-article","created":{"date-parts":[[2013,12,4]],"date-time":"2013-12-04T11:49:58Z","timestamp":1386157798000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Abacavir-based triple nucleoside regimens for maintenance therapy in patients with HIV"],"prefix":"10.1002","volume":"2013","author":[{"given":"Mario","family":"Cruciani","sequence":"first","affiliation":[{"name":"ULSS 20 Verona; Center of Community Medicine and Infectious Diseases Service; Via Germania, 20 Verona Italy 37135"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlo","family":"Mengoli","sequence":"additional","affiliation":[{"name":"Universit\u00e0 di Padova; Department of Histology, Microbiology and Medical Biotechnology; Via Aristide Gabelli, 63 PADOVA Italy 35121"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Serpelloni","sequence":"additional","affiliation":[{"name":"ULSS 20 Verona; Dipartimento delle Dipendenze; Via Germania, 20 37135 Verona Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saverio G","family":"Parisi","sequence":"additional","affiliation":[{"name":"Universit\u00e0 di Padova; Department of Histology, Microbiology and Medical Biotechnology; Via Aristide Gabelli, 63 PADOVA Italy 35121"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina","family":"Malena","sequence":"additional","affiliation":[{"name":"ULSS 20 Verona; Center of Community Medicine; Via Germania, 20 37135 Verona Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oliviero","family":"Bosco","sequence":"additional","affiliation":[{"name":"ULSS 20 Verona; Center of Community Medicine; Via Germania, 20 37135 Verona Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,6,5]]},"reference":[{"key":"10.1002\/14651858.CD008270.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1097\/01.qai.0000164249.33851.3a","article-title":"Antiretroviral treatment simplification with 3 NRTIs or 2 NRTIs plus nevirapine in HIV-1-infected patients treated with successful first-line HAART","volume":"39","author":"Bonjoch","year":"2005","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"12","key":"10.1002\/14651858.CD008270.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1097\/00002030-200108170-00009","article-title":"Simplification with ABC-based triple nucleoside therapy vs continued PI-based ART in HIV-1-infected patients with undetectable plasma HIV-1 RNA (CNA300017)","volume":"15","author":"Clumeck","year":"2001","journal-title":"AIDS"},{"issue":"2","key":"10.1002\/14651858.CD008270.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1046\/j.1468-1293.2003.00139.x","article-title":"TRIZAL study: switching from successful HAART to Trizivir (abacavir-lamivudine-zidovudine combination tablet): 48 weeks efficacy, safety and adherence results","volume":"4","author":"Katlama","year":"2003","journal-title":"HIV Medicine"},{"key":"10.1002\/14651858.CD008270.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1471-2334-5-2","article-title":"Substituting abacavir for hyperlipidemia-associated protease inhibitors in HAART regimens improves fasting lipid profiles, maintains virologic suppression, and simplifies treatment","volume":"5","author":"Keiser","year":"2005","journal-title":"BMC Infect Dis."},{"key":"10.1002\/14651858.CD008270.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1086\/375598","article-title":"Outcome of 2 simplification strategies for the treatment of human immunodeficiency virus type 1 infection.","volume":"37","author":"Maggiolo","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1002\/14651858.CD008270.pub2-BIB0007|cit6","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1056\/NEJMoa021589","article-title":"Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection","volume":"349","author":"Mart\u00ednez","year":"2003","journal-title":"N Engl J Med."},{"key":"10.1002\/14651858.CD008270.pub2-BIB0008|cit7","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1097\/QAD.0b013e3280121ab1","article-title":"Three-year follow-up of protease inhibitor-based regimen simplification in HIV-infected patients.\u00a0\u00a0AIDS","volume":"21","author":"Mart\u00ednez","year":"2007","journal-title":"AIDS"},{"key":"10.1002\/14651858.CD008270.pub2-BIB0009|cit8","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1097\/01.aids.0000181010.85255.3c","article-title":"Genotypic and phenotypic resistance patterns at virological failure in a simplification trial with nevirapine, efavirenz or abacavir","volume":"19","author":"Ochoa de Echaguen","year":"2005","journal-title":"AIDS"},{"key":"10.1002\/14651858.CD008270.pub2-BIB0006|cit9","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1097\/01.aids.0000171405.46113.bf","article-title":"Metabolic benefits 24 months after replacing a protease inhibitor with abacavir, efavirenz or nevirapine","volume":"19","author":"\u00a0Fisac","year":"2005","journal-title":"AIDS"},{"key":"10.1002\/14651858.CD008270.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1086\/340312","article-title":"A randomized trial of simplified maintenance therapy with abacavir, lamivudine, and zidovudine in human immunodeficiency virus infection","volume":"185","author":"Opravil","year":"2002","journal-title":"J Infect Dis"},{"key":"10.1002\/14651858.CD008270.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1089\/apc.2009.0236","article-title":"Abacavir\/lamivudine\/zidovudine maintenance after standard induction in antiretroviral therapy-na\u00efve patients: FREE randomized trial interim results","volume":"24","author":"Sprenger","year":"2010","journal-title":"AIDS Patient Care STDS"},{"key":"10.1002\/14651858.CD008270.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1097\/01.aids.0000247581.93201.79","article-title":"Switch from a first virologically effective protease inhibitor-containing regimen to a regimen containing efavirenz, nevirapine or abacavir","volume":"20","author":"Abgrall","year":"2006","journal-title":"AIDS"},{"key":"10.1002\/14651858.CD008270.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1086\/509578","article-title":"Comparative biological and clinical outcomes after a switch from a virologically unsuccessful first protease inhibitor-containing antiretroviral combination to a 3-drug regimen containing efavirenz, nevirapine, or abacavir.","volume":"44","author":"Abgrall","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1002\/14651858.CD008270.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1093\/jac\/dkr208","article-title":"Comparative effectiveness of continuing a virologically effective first-line boosted protease inhibitor combination or of switching to a three-drug regimen containing either efavirenz, nevirapine or abacavir","volume":"66","author":"Bommenel","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"10.1002\/14651858.CD008270.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1177\/135965350300800104","article-title":"Simplification of protease inhibitor-containing regimens with efavirenz, nevirapine or abacavir: safety and efficacy outcomes","volume":"8","author":"Chiesa","journal-title":"Antiviral Therapy"},{"key":"10.1002\/14651858.CD008270.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1086\/504265","article-title":"A comparison between abacavir and efavirenz as the third drug used in combination with a background therapy regimen of 2 nucleoside reverse-transcriptase inhibitors in patients with initially suppressed viral loads","volume":"194","author":"Cozzi-Lepri","year":"2006","journal-title":"J Infect Dis"},{"issue":"18","key":"10.1002\/14651858.CD008270.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1056\/NEJMoa031772","article-title":"Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection.","volume":"350","author":"Gulick","year":"2004","journal-title":"N Engl J Med"},{"issue":"Suppl. 1","key":"10.1002\/14651858.CD008270.pub2-BIB0018|cit18","first-page":"27","article-title":"Simplification to lamivudine, zidovudine, and abacavir therapy: impact on adherence, clinical outcome, and economic issues","volume":"28","author":"Ibarra Barrueta","year":"2004","journal-title":"Farmacia Hospitalaria"},{"issue":"2","key":"10.1002\/14651858.CD008270.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/j.1468-1293.2006.00346.x","article-title":"A prospective, 96-week study of the impact of Trizivir, Combivir\/nelfinavir, and lamivudine\/stavudine\/nelfinavir on lipids, metabolic parameters and efficacy in antiretroviral-naive patients: effect of sex and ethnicity.","volume":"7","author":"Kumar","year":"2006","journal-title":"HIV Medicine"},{"key":"10.1002\/14651858.CD008270.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1742-6405-6-3","article-title":"A randomized, controlled trial of initial anti-retroviral therapy with abacavir\/lamivudine\/zidovudine twice-daily compared to atazanavir once-daily with lamivudine\/zidovudine twice-daily in HIV-infected patients over 48 weeks (ESS100327, the ACTION Study)","volume":"6","author":"Kumar","year":"2009","journal-title":"AIDS Res Ther"},{"key":"10.1002\/14651858.CD008270.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1177\/135965350300800211","article-title":"CNA3007 Study Group. Triple nucleoside combination zidovudine\/lamivudine\/abacavir versus zidovudine\/lamivudine\/nelfinavir as first-line therapy in HIV-1-infected adults: a randomized trial","volume":"8","author":"Matheron","year":"2003","journal-title":"Antivir Ther"},{"issue":"7","key":"10.1002\/14651858.CD008270.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1097\/00002030-200205030-00022","article-title":"Switching to zidovudine plus lamivudine plus abacavir maintains viral suppression in patients with high viral load before antiretroviral therapy: a retrospective clinical cohort analysis","volume":"16","author":"Moyle","year":"2002","journal-title":"AIDS"},{"key":"10.1002\/14651858.CD008270.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1111\/j.1468-1293.2009.00786.x","article-title":"Nevirapine\/zidovudine\/lamivudine has superior immunological and virological responses not reflected in clinical outcomes in a 48-week randomized comparison with abacavir\/zidovudine\/lamivudine in HIV-infected Ugandan adults with low CD4 cell counts","volume":"11","author":"Munderi","year":"2010","journal-title":"HIV Medicine"},{"key":"10.1002\/14651858.CD008270.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1093\/jac\/dkh515","article-title":"A randomized study comparing a three- and four-drug HAART regimen in first-line therapy (QUAD study)","volume":"55","author":"Orkin","year":"2005","journal-title":"J Antimicrob Chemother"},{"key":"10.1002\/14651858.CD008270.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1097\/QAD.0b013e3282f1560b","article-title":"Successful simplification of protease inhibitor-based HAART with triple nucleoside regimens in children vertically infected with HIV.","volume":"21","author":"Palma","year":"2007","journal-title":"AIDS"},{"issue":"9","key":"10.1002\/14651858.CD008270.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1001\/jama.285.9.1155","article-title":"Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trial","volume":"285","author":"Staszewski","year":"2001","journal-title":"JAMA"},{"issue":"7","key":"10.1002\/14651858.CD008270.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1185\/030079904125004006","article-title":"Triple nucleoside treatment with abacavir plus the lamivudine\/zidovudine combination tablet (COM) compared to indinavir\/COM in antiretroviral therapy-naive adults: results of a 48-week open-label, equivalence trial (CNA3014)","volume":"20","author":"Vibhagool","year":"2004","journal-title":"Curr Med Res Opin"},{"key":"10.1002\/14651858.CD008270.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1097\/QAD.0b013e3282efacb1","article-title":"Predictors of optimal viral suppression in patients switched to abacavir, lamivudine, and zidovudine: the Swiss HIV Cohort Study","volume":"21","author":"Wolbers","year":"2007","journal-title":"AIDS"},{"key":"10.1002\/14651858.CD008270.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/QAI.0b013e3181a56de5","article-title":"Lopinavir-ritonavir monotherapyversus lopinavir-ritonavir and 2 nucleosidesfor maintenance therapy of HIV: 96-week analysis","volume":"51","author":"Arribas","year":"2009","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1002\/14651858.CD008270.pub2-BIB0030|cit30","unstructured":"Bedimo R \u00a0 Westfall A \u00a0 Drechsler H Tebas P Abacavir use and risk of acute myocardial infarction and cerebrovascular disease in the HAART era IAS 2009, Cape Town, 19-22 July 2009 2009 Abst. MOAB202"},{"key":"10.1002\/14651858.CD008270.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1097\/QAI.0b013e31819ff0e6","article-title":"Risk of Myocardial Infarction and Abacavir therapy: No increased risk across 52 Glaxo-Smith Kline-sponsored clinical trials in adult subjects","volume":"51","author":"Brothers","year":"2009","journal-title":"Journal of the Acquired Immune Deficiency Syndrome."},{"issue":"17","key":"10.1002\/14651858.CD008270.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1097\/00002030-200311210-00007","article-title":"A Meta-analysis of randomized controlled trials of simplified versus continued protease inhibitor-based antiretroviral therapy in HIV-1-infected patients.","volume":"17","author":"Bucher","year":"2003","journal-title":"AIDS"},{"key":"10.1002\/14651858.CD008270.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1097\/QAD.0b013e328349c6ee","article-title":"Abacavir Use and Cardiovascular Disease Events: a Meta-analysis of Published and unpublished Data","volume":"25","author":"Cruciani","year":"2011","journal-title":"AIDS"},{"issue":"17","key":"10.1002\/14651858.CD008270.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa062744","article-title":"Class of antiretroviral drugs and the risk of myocardial infarction","volume":"356","author":"The DAD Study Group","year":"2007","journal-title":"New England Journal of Medicine"},{"issue":"9622","key":"10.1002\/14651858.CD008270.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1016\/S0140-6736(08)60423-7","article-title":"Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration","volume":"371","author":"Sabin","year":"2008","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD008270.pub2-BIB0036|cit36","first-page":"1391","article-title":"Virological response to a triple nucleoside\/nucleotide analogue regimen over 48weeks in HIV-1-infected adults in Africa. AIDS. Jun 26 2006;20(10):1391-1399.","volume":"20","author":"DART Virology Group and Trial Team","year":"2006","journal-title":"AIDS"},{"key":"10.1002\/14651858.CD008270.pub2-BIB0037|cit37","unstructured":"Department of Health and Human Services Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. www.aidsinfo.nih.gov\/ContentFiles\/AdultandAdolescentGL.pdf"},{"key":"10.1002\/14651858.CD008270.pub2-BIB0038|cit38","unstructured":"Department of Health and Human Services Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents www.aidsinfo.nih.gov\/ContentFiles\/AdultandAdolescentGL.pdf January 2011"},{"key":"10.1002\/14651858.CD008270.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1097\/QAD.0b013e328328f789","article-title":"Greater decrease in bone mineral density with protease inhibitor regimens compared with nonnucleoside reverse transcriptase inhibitor regimens in HIV-1 infected naive patients","volume":"23","author":"Duvivier","year":"2009","journal-title":"AIDS"},{"key":"10.1002\/14651858.CD008270.pub2-BIB0040|cit40","unstructured":"European AIDS Clinical Society Guidelines. Clinical management and treatment of HIV infected Adults in Europe\u00a0 http:\/\/www.europeanaidsclinicalsociety.org\/guidelines.asp November 2009"},{"issue":"7109","key":"10.1002\/14651858.CD008270.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"British Medical Journal"},{"issue":"7414","key":"10.1002\/14651858.CD008270.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"32","author":"Higgins","year":"2003","journal-title":"British Medical Journal"},{"key":"10.1002\/14651858.CD008270.pub2-BIB0043|cit43","doi-asserted-by":"crossref","unstructured":"Higgins JPT Green S Cochrane Handbook for Systematic Reviews of Interventions 5.0.0 The Cochrane Collaboration. Available from www.Cochrane-handbook.org 2008","DOI":"10.1002\/9780470712184"},{"key":"10.1002\/14651858.CD008270.pub2-BIB0044|cit44","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2. [updated September 2008]. Available from www.cochrane-handbook.org 2009","author":"Higgins","year":"2009"},{"key":"10.1002\/14651858.CD008270.pub2-BIB0045|cit45","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0","author":"Higgins","year":"March 2011"},{"key":"10.1002\/14651858.CD008270.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1097\/QAD.0b013e32833dec20","article-title":"Efficacy of darunavir\/ritonavir maintenance monotherapy in patients with HIV-1 viral suppression: a randomized open-label, noninferiority trial, MONOI-ANRS 136","volume":"24","author":"Katlama","year":"2010","journal-title":"AIDS"},{"issue":"2","key":"10.1002\/14651858.CD008270.pub2-BIB0047|cit47","first-page":"70","article-title":"Triple-nucleoside analog antiretroviral therapy: is there still a role in clinical practice? A review","volume":"7","author":"Kessler","year":"2005","journal-title":"Medscape General Medicine"},{"key":"10.1002\/14651858.CD008270.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"e41390","DOI":"10.1371\/journal.pone.0041390","article-title":"Similar evolution of cellular HIV-1 DNA level in darunavir\/ritonavir monotherapy versus triple therapy in MONOI-ANRS136 trial over 96 weeks.","volume":"7","author":"Lambert-Niclot","year":"2012","journal-title":"PLoS One"},{"key":"10.1002\/14651858.CD008270.pub2-BIB0049|cit49","unstructured":"Lang S Mary-Krause M Cotte L Impact of specific NRTI and PI exposure on the risk of myocardial infarction: a case-control study nested within FHDH ANRS CO4 16th Conference on Retroviruses and Opportunistic Infections (CROI), Montreal, abstract 43LB, 2009. 2009"},{"key":"10.1002\/14651858.CD008270.pub2-BIB0050|cit50","unstructured":"Lundgren J Reiss P Worm S Risk of miocardial infarction with exposure to specific ARV from the PI, NNRTI, and NRTI drug classes: The D:A:D Study Abstract of the 16th Conference on retrovirus and opportunistic Infection (CROI), Montreal, february 2009. Abst. 44LB 2009"},{"key":"10.1002\/14651858.CD008270.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1056\/NEJMoa0706135","article-title":"HLA-B*5701 Screening for hypersensitivity to abacavir","volume":"358","author":"Mallal","year":"2008","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD008270.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1056\/NEJMoa021589","article-title":"Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection","volume":"349","author":"Mart\u00ednez","year":"2003","journal-title":"N Engl J Med."},{"key":"10.1002\/14651858.CD008270.pub2-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1097\/QAD.0b013e3280121ab1","article-title":"Three-year follow-up of protease inhibitor-based regimen simplification in HIV-infected patients.\u00a0\u00a0AIDS","volume":"21","author":"Mart\u00ednez","year":"2007","journal-title":"AIDS"},{"key":"10.1002\/14651858.CD008270.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1097\/01.aids.0000181010.85255.3c","article-title":"Genotypic and phenotypic resistance patterns at virological failure in a simplification trial with nevirapine, efavirenz or abacavir","volume":"19","author":"Ochoa de Echaguen","year":"2005","journal-title":"AIDS"},{"key":"10.1002\/14651858.CD008270.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1097\/00002030-200411050-00019","article-title":"Long-term efficacy after switch from protease inhibitor-containing highly active antiretroviral therapy toabacavir, lamivudine, and zidovudine","volume":"18","author":"Opravil","year":"2004","journal-title":"AIDS"},{"key":"10.1002\/14651858.CD008270.pub2-BIB0056|cit56","unstructured":"Pappa K Hernandez J Ha B ABC\/3TC shows robust virologic responses in ART-naive patients for baseline (BL) viral loads of >100,000c\/mL and <100,000c\/mL by endpoint used in ACTG5202 XVII International AIDS Conference (AIDS 2008). Mexico City. August 3-8, 2008. Abstract THAB0304 2008"},{"key":"10.1002\/14651858.CD008270.pub2-BIB0057|cit57","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0","author":"Higgins","year":"March 2011"},{"key":"10.1002\/14651858.CD008270.pub2-BIB0058|cit58","doi-asserted-by":"crossref","unstructured":"Ribaudo HJ Benson CA Zheng Y ACTG A5001\/ALLRT Protocol Team No risk of myocardial infarction associated with initial antiretroviral treatment containing abacavir: short and long-term results from ACTG A5001\/ALLRT. Clinical Infectious Diseases 2011 929 40","DOI":"10.1093\/cid\/ciq244"},{"issue":"12","key":"10.1002\/14651858.CD008270.pub2-BIB0059|cit59","first-page":"269","article-title":"Switch to abacavir-based triple nucleoside regimens in HIV-1 infected patients never treated with suboptimal antiretroviral therapy: a review","volume":"12","author":"Rizzardini","year":"2006","journal-title":"Medical Science Monitor"},{"key":"10.1002\/14651858.CD008270.pub2-BIB0060|cit60","unstructured":"Sax P Tierney C Collier A ACTG 5202: shorter time to virologic failure with ABC\/3TC than TENOFOVIR\/FTC in treatment-naive subjects with HIV RNA >100,000 XVII International AIDS Conference (AIDS 2008). Mexico City. August 3-8, 2008. Abstract THAB0303 2008"},{"issue":"14","key":"10.1002\/14651858.CD008270.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"F17","DOI":"10.1097\/QAD.0b013e32830fe35e","article-title":"Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients","volume":"22","author":"Strategies for Management of Anti-Retroviral","year":"2008","journal-title":"AIDS"},{"key":"10.1002\/14651858.CD008270.pub2-BIB0062|cit62","unstructured":"Smith KY Fine D Patel P Similarity in efficacy and safety of abacavir\/lamivudine (ABC\/3TC) compared to tenofovir\/emtricitabine (TENOFOVIR\/FTC) in combination with QD lopinavir\/ritonavir (LPV\/r) over 96 weeks in the HEAT study XVII International AIDS Conference (AIDS 2008). Mexico City. August 3-8, 2008. Abstract LBPE1138 2008"},{"key":"10.1002\/14651858.CD008270.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1093\/jac\/dkr504","article-title":"Long-term efficacy of darunavir\/ritonavir monotherapy in patients with HIV-1 viral suppression: week 96 results from the MONOI ANRS 136 study.","volume":"67","author":"Valantin","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"10.1002\/14651858.CD008270.pub2-BIB0064|cit64","volume-title":"SF-36 Health Survey manual and interpretation guide","author":"Ware","year":"1993"},{"key":"10.1002\/14651858.CD008270.pub2-BIB0065|cit65","unstructured":"World Health Organization Antiretroviral therapy for HIV infection in adults and adolescents. Recommendations for a public health approach. 2010 revision http:\/\/whqlibdoc.who.int\/publications\/2010\/9789241599764_eng.pdf 2010"},{"key":"10.1002\/14651858.CD008270.pub2-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1086\/649897","article-title":"Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study","volume":"201","author":"Worm","year":"2010","journal-title":"J Infect Dis"},{"key":"10.1002\/14651858.CD008270.pub2-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1023\/A:1018460132567","article-title":"Applications of the Medical Outcomes Study health-related quality of life measures in HIV\/AIDS.","volume":"6","author":"Wu","year":"1997","journal-title":"Qual Life Res"},{"issue":"917-25","key":"10.1002\/14651858.CD008270.pub2-BIB0068|cit68","article-title":"Metabolic benefits 24 months after replacing a protease inhibitor with abacavir, efavirenz or nevirapine","volume":"19","author":"\u00a0Fisac","year":"2005","journal-title":"AIDS"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/14651858.CD008270.pub2\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,17]],"date-time":"2024-08-17T10:27:21Z","timestamp":1723890441000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD008270.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane HIV\/AIDS Group","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2013,6,5]]},"references-count":68,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2013,6]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd008270.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,6,5]]}}}